Kyverna Therapeutics, Inc.

KYTX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$37-$42-$45-$37
Dep. & Amort.$0$1$1$1
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$3$2$0
Change in WC-$9$8-$2$0
Other Non-Cash$2-$1-$1-$0
Operating Cash Flow-$43-$32-$45-$37
Investing Activities
PP&E Inv.-$0-$0$0-$1
Net Acquisitions$0$0$0$0
Inv. Purchases-$73-$95-$81-$127
Inv. Sales/Matur.$96$124$85$157
Other Inv. Act.$0-$0$2$0
Investing Cash Flow$23$29$6$29
Financing Activities
Debt Repay.-$0-$0-$0-$0
Stock Issued$2-$0-$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$0-$0$0$0
Financing Cash Flow$1-$1-$0-$0
Forex Effect$0$0$0$0
Net Chg. in Cash-$19-$3-$40-$8
Supplemental Information
Beg. Cash$53$57$97$105
End Cash$34$54$57$97
Free Cash Flow-$44-$32-$45-$38